Hematopoietic Stem Cell TransplantationTransplantation, HomologousGraft vs Host DiseaseTransplantation ConditioningHematopoietic Stem CellsHematologic NeoplasmsStem Cell TransplantationTransplantation, AutologousGraft vs Leukemia EffectTransplantation ChimeraPeripheral Blood Stem Cell TransplantationTissue DonorsMyeloablative AgonistsTreatment OutcomeBone Marrow TransplantationBusulfanGraft vs Tumor EffectHistocompatibilityChimerismWhole-Body IrradiationLeukemiaRecurrenceRetrospective StudiesHistocompatibility TestingStem CellsVidarabineAllograftsGraft SurvivalHematologic DiseasesCord Blood Stem Cell TransplantationLeukemia, Myeloid, AcuteMyelodysplastic SyndromesSiblingsLymphocyte TransfusionHLA AntigensImmunosuppressive AgentsRemission InductionPrecursor Cell Lymphoblastic Leukemia-LymphomaHepatic Veno-Occlusive DiseaseSurvival RateCytomegalovirus InfectionsHematopoiesisSurvival AnalysisLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAcute DiseaseTime FactorsTransplantation ImmunologyCombined Modality TherapyDisease-Free SurvivalLeukemic InfiltrationAnemia, AplasticT-LymphocytesTransplantation, IsogeneicCystitisMinor Histocompatibility AntigensAntigens, CD34Lymphocyte DepletionFlow CytometryOpportunistic InfectionsHematopoietic Stem Cell MobilizationBone Marrow CellsMultiple MyelomaSevere Combined ImmunodeficiencyNeoplasm, ResidualFollow-Up StudiesSalvage TherapyLymphoproliferative DisordersAntilymphocyte SerumCyclophosphamideCytomegalovirusMice, Inbred C57BLCell DifferentiationBronchiolitis ObliteransLiver TransplantationRisk FactorsImmunocompromised HostBlood Group IncompatibilityPhotopheresisLeukemia, MyeloidMycosesPrognosisImmunosuppressionCell LineageFatal OutcomeFetal BloodSurvivorsAntineoplastic Combined Chemotherapy ProtocolsUnrelated DonorsPrimary MyelofibrosisMesenchymal Stem Cell TransplantationGanciclovirBone MarrowCell TransplantationChronic DiseaseIsoantigensCytarabineStem Cell NicheEmbryonic Stem CellsGraft RejectionIncidence